title: Overcoming platinum drug resistance with copper-lowering agents.
abstract: Platinum (Pt)-based antitumor agents have been the mainstay of cancer chemotherapy for the last three decades. While multiple mechanisms are responsible for treatment failure, deficiency in drug transport is an important contributor. The human high-affinity copper (Cu) transporter-1 (hCtr1) can also transport Pt-based drugs including cisplatin (cDDP) and carboplatin. Reduced hCtr1 expression frequently occurs in cDDP-resistant cell lines and in cancer in patients who failed chemotherapy with these drugs. We previously demonstrated that Cu chelation induces the expression of transcription factor Sp1 which binds the promoters of Sp1 and hCtr1, thereby, up-regulating their expression, whereas Cu overload shuts down hCtr1 and Sp1 expression by dissociating Sp1 from their promoter promoters. Thus, mammalian Cu homeostasis is transcriptionally regulated within a loop consisting of Sp1, hCtr1, and Cu in a three-way mutually regulated manner. These findings suggest that it is feasible to module cDDP transport capacity through intervention of mammalian Cu homeostasis. Indeed, we found that cDDP resistance can be overcome by Cu-lowering agents through enhanced hCtr1 expression by up-regulation of Sp1 in cultured cells. This discovery provided a mechanistic basis for the ongoing clinical study using Cu chelator to overcome cDDP resistance in ovarian cancer chemotherapy. Preliminary study using copper chelator (trientine) for enhancing the treatment efficacy of carboplatin in 5 ovarian cancer patients showed encouraging results. This short review describes the perspectives of using Cu-lowering agents in overcoming Pt resistance in cancer chemotherapy.
authors.affiliation: Department of Translational Molecular Pathology (Unit 951), The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030, USA. tkuo@mdanderson.org.
authors.forename: Helen H W
authors.initials: HH
authors.lastname: Chen
authors.forename: Macus Tien
authors.initials: MT
authors.lastname: Kuo
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000378:metabolism / Q000494:pharmacology*; D001692:Biological Transport / Q000187:drug effects; D027682:Cation Transport Proteins / Q000378:metabolism; D002614:Chelating Agents / Q000494:pharmacology*; D002945:Cisplatin / Q000378:metabolism / Q000494:pharmacology*; D002986:Clinical Trials as Topic; D003300:Copper / Q000378:metabolism*; D000079923:Copper Transporter 1; D019008:Drug Resistance, Neoplasm; D006801:Humans; D013312:Stress, Physiological / Q000187:drug effects
chemical_list: D000970:Antineoplastic Agents; D027682:Cation Transport Proteins; D002614:Chelating Agents; D000079923:Copper Transporter 1; C490079:SLC31A1 protein, human; D003300:Copper; D002945:Cisplatin
keywords: Cisplatin; copper chelator; high-affinity human copper transporter 1 (hCtr1); review